Skip to content
,
Open navigation
eller
Skip to contact information
.
Copyright © Inderes 2011 - present. All rights reserved.
Latest
Börs
Aktiejämförelse
Kalender
Aktieanalys
Artiklar
inderesTV
Portfölj
Forum
About us
Våra kunder
Team
Settings
Collapse
Språk
Copyright © Inderes 2011 - present. All rights reserved.
Search site
Logga in
Logga in
för att få aviseringar
Antti Siltanen
Analyst
Coverage
Nexstim
BBS-Bioactive Bone Substitutes
Faron Pharmaceuticals
Bioretec
Modulight
Orion
Latest content
Showing
Alla typer av innehåll
Nexstim reported results on the use of accelerated iTBS protocol
Analytikerkommentar
2023-06-09
av
Antti Siltanen
Nexstim
Nightingale announced new patent approvals
Analytikerkommentar
2023-05-24
av
Antti Siltanen
,
Frans-Mikael Rostedt
Nightingale Health
Signs of recovery in the funding of biotechnology
Analytikerkommentar
2023-05-19
av
Antti Siltanen
Aiforia Technologies
Faron Pharmaceuticals
Nexstim
Bioretec
Nexstim received marketing authorization for its NBS6 product also in Europe
Analytikerkommentar
2023-05-19
av
Antti Siltanen
Nexstim
Modulight: Start of the year was still difficult
Aktieanalys
2023-05-02
av
Antti Siltanen
Modulight
Faron Pharmaceuticals: BEXMAB study’s good momentum supports valuation
Aktieanalys
2023-04-17
av
Antti Siltanen
Faron Pharmaceuticals
Modulight: Towards profitable growth
Video
2023-03-27
av
Antti Siltanen
,
Jeremias Makkonen
Modulight
According to FDA, bexmarilimab is safe, but dosage requires additional evidence
Analytikerkommentar
2023-03-23
av
Antti Siltanen
Faron Pharmaceuticals
Nexstim’s guidance indicates profitability turnaround but industry companies seem to continue making losses
Analytikerkommentar
2023-03-21
av
Antti Siltanen
Nexstim
Modulight: Laser company being calibrated towards growth
Omfattande aktieanalys
2023-03-20
av
Antti Siltanen
Modulight
Ladda mer